Cancer-Diagnosis-and-Therapy-Congress-17June

For more information please contact Ajay Nimbalkar, MnM Conferences
ajay.nimbalkar@mnmconferences.com | +9120 6704 6816 1
MnM CONFERENCES
MnM Conferences is pleased to announce the inaugural Cancer Diagnosis & Therapy Congress on 3rd
&4th
September, 2015 London,
UK. This congress will bring 150+ experts from industries, hospitals, research centers and universities across the globe to address the
advanced diagnostic technologies and novel targeted therapies & therapeutics approaches to combat cancer.
Key Discussions at the Conference
• Interventional radiological techniques in cancer diagnosis
• Immunotherapy, molecular targeted therapy, cell therapy & precision medicine
• Novel biomarkers in cancer diagnosis and prognosis
• Nanotechnology in cancer therapy
• Biosensor for cancer detection
• Functional genomics in cancer
Distinguished Speakers
Dr. James F. Smothers
Sr. Director & Head of Discovery Research
Immuno-Oncology & Combinations DPU
Oncology R&D, GlaxoSmithKline, USA
Prof. Stefan Gluck
Vice President
Global Medical Affairs
Celgene, USA
Prof. Andreas Schätzlein
CEO, Nanomerics Ltd, UK
Chair in Translational Therapeutics
University College Londonm, UK
Dr. Leonard M. Reyno
Senior Vice President & Chief Medical Officer
Agensys Inc- Astellas Pharma
USA
Prof. Riccardo A. Audisio
University of Liverpool
President European Society
of Surgical Oncologists & BASO, UK
Dr. Francisco Gonzalez
Hemato - Oncology Medical Manager
The Janssen Pharmaceutical Companies
of Johnson & Johnson, Panama
www.mnmconferences.com/cancer-diagnosis-therapy-congress.html
For Researchers:
• Get a global platform to present your research & innovation
• Look at addressing challenges in oncology research through various case studies
• Look at collaborations and securing funds by showcasing your research to industries
• Stay updated with recent discoveries and technology
• Engage in knowledge sharing sessions with global experts
For PharmaIndustry:
• Look at addressing challenges in bringing novel & cost effective therapeutics into market
• Meet leading scientists and doctors for research collaboration and product review
• Look at products and solutions by other players in the market
• Interact with researchers for knowledge sharing and technology transfer
For Doctors:
• An international platform to interact with experts worldwide
• Opportunity to update yourself with advanced treatment & diagnosis strategies
• Get to meet leading pharma companies to upgrade yourself with upcoming theraputic products
• Network with peers from hospitals and research centres
What’s in it for you?
One of a kind conference covering advances
in both Cancer Diagnosis & Therapy through
20+ case studies15+ research presentations
20+ international speakers
50+ poster sessions10+ industry speakers15+ oncologists10+ research leaders

MnM CONFERENCES
2
MnM CONFERENCES
Confirmed Speakers
Dr. John Brognard
Group Leader
Signalling Networks in
Cancer, CRUK, The University
of Manchester, UK
Dr. Fernando Calvo
Team Leader
Division of Cancer Biology
The Institute of Cancer
Research, UK
Dr. Gianni Mura
Surgical Oncologist and
General Surgeon
Valdarno Hospital, Arezzo
Italy
Dr. James M Flanagan
Department of Surgery
& Cancer
Imperial College London, UK
Hassan Z Malik
University Hospital Aintree
Honorary Secretary
British Association of Surgical
Oncology, UK
Dr. Claus Jorgensen
Group Leader,
Systems Oncology
The University
of Manchester, UK
Dr. Ilaria Malanchi
Group Leader, Tumour Host
Interaction Lab
London Research Institute, UK
Prof. Jude Fitzgibbon
Barts Cancer Institute
Queen Mary University of
London, UK
Prof. Pedro Estrela
Department of Electronic &
Electrical Engineering
University of Bath, UK
Dr. Alan G. Ramsay
Team Leader, Lymphoma
Immunology
Department of Hemato-
Oncology, KCL, UK
Prof. Marek K. Janiak
Head Dept. of Radiobiology
& Radiation Protection
Military Institute of Hygiene
& Epidemiology, Poland
Dr. Esther Baena
Group Leader
Cancer Research UK
Manchester Institute, UK
Prof. Robert Brown
Head of Division of Cancer
Imperial College London
UK
Dr. Alan Prem Kumar
Cancer Science Institute of
Singapore
Dr. Michela Garofalo
Group Leader
Transcriptional Networks in
Lung Cancer
CRUK, UK
Dr. Christos Christopoulos
Consultant,
Radiation Oncologist
Metropolitan Hospital,
Greece
Prof. Robert Hawkins
Director of Medical
Oncology
Christie Hospital
Cancer Research UK, UK
William P. Chastain
Director & Founder
APeX Disease Reserch
Institute, USA
Prof. Charlotte Bevan
Androgen Signalling
Laboratory, Imperial
Centre for Translational
& Experimental Medicine,
London, UK
Prof. Pedro Rondot Radío
University of Buenos Aires
Army Social Security
Argentina
Prof. Kathryn Ball
Chair in Biochemistry and
Cell Signalling
Edinburgh Cancer Research
Centre, UK
Dr. Dana Flavin-Konig
Executive Director
Foundation for Collaborative
Medicine and Research
USA
Prof. Michelle Garrett
University of Kent
General Secretary
The British Association for
Cancer Research, UK
Prof. Peter J. Parker
London Research Institute
Lincoln’s Inn Fields
King’s College London, UK
Prof. Kristijan Ramadan
Senior Group Leader
CRUK/MRC Oxford Institute
for Radiation Oncology, UK
Prof. Edward Leen
Chair of Radiology
Imperial College London
Hammersmith Hospital
Campus, UK
Prof. Jacqui Shaw
Dept. of Cancer Studies,
University of Leicester, UK
Prof. Michael Lisanti
Director of the Breakthrough
Breast Cancer Research Unit
Cancer Research UK
Manchester Institute, UK
Prof. Hani Gabra
Director, Ovarian Cancer Action
Research Centre
Prof. Ken Mills
Chair, Experimental Haema-
tology, Centre for Cancer
Research and Cell Biology
Queen’s University Belfast, UK
Prof. Lesley Fallowfield
Director: SHORE-C
Brighton & Sussex Medical
School, University of Sussex
UK
Prof. Thomas J. Vogl
Director, Dept. of Diagnostic
and Interventional Radiology,
Wolfgang Goethe-University
Germany
Prof. Karim Nayernia
Co-Director & Head
Heali Institute for
Personalized Medicine
Cambridge, UK
Dr. Michael Meyers
VP, Oncology
Scientific Innovation Lead at
Janssen, UK

MnM CONFERENCES
Day 1 Thursday, September 3rd
, London, UK
Agenda
08.00-08.50 Registration & Refreshments
08.50-09.00 Welcome Address & Chairperson’s Opening Remarks Chairperson: TBC
09:00-09:30 Keynote Address
Nano-enabled delivery of cancer therapies
A key objective of cancer drug discovery is to find efficacious compounds with a favourable side effect profile. Current approaches
therefore focus on the discovery of highly specific compounds that target specific molecular targets with a clear role in molecular
pathology of cancer. However, success of such drugs is not only dependent on to the specificity of the interaction between drug
and target but also to the ability to selectively achieve high drug concentrations in the tumour.
Frequently, the translation of such highly specific compounds, and in particular biologics, into actual medicines present challenges
due to bioavailability problems. Equally, the capability to selectively control drug distribution offers a general strategy to further
enhance the specificity of these and other types of cancer therapies.
The aim of our research is therefore the selective control of drug distribution, in order to maximise effects on the tumour and
minimise off target effects. In order to achieve this level of control, we have engineered molecules to create supramolecular
systems that allow the development of nano-enabled anti-cancer medicines.
CONFIRMED: Prof. Andreas Schätzlein
CEO, Nanomerics Ltd, UK
Chair in Translational Therapeutics
University College London, UK
09:30-10:00
Solution Provider Presentation
For sponsorship opportunities please contact Steve Hambrook
at steve.h@mnmconferences.com
Stream-1 Advancements in Cancer
Diagnosis: Methods, Technology
Applications
Therapy: Methods, Technology
Applications
10:00-10:05
10:05-10:30
Stream Chair: TBC Stream Chair: TBC
Case study: Electrochemical Biosensors for
Prostate Cancer Diagnosis
• Electrochemical biosensors have great promise for point-
of-care diagnosis
• Novel approaches have been established for the accurate
and sensitive detection of a range of biomarkers
• Devices measuring simultaneously several prostate cancer
biomarkers can provide early diagnosis and prognosis of
the disease, ultimately informing therapies
CONFIRMED:
Dr. Pedro Estrela
Associate Professor, Department of Electronic
Electrical Engineering, University of Bath, UK
Biosensors in Cancer Diagnosis
Immunotherapy for Cancer:
Technology Application
Immunotherapy in Lymphoma
• The tumour microenvironment (TME) in lymphoma
• Immune evasion mechanisms
• Immune checkpoint blockade (ICB) immunotherapy
• Immunomodulatory drug (IMiD) immunotherapy
CONFIRMED:
Dr. Alan G. Ramsay
Team Leader, Lymphoma Immunology,
Department of Hemato-Oncology, King’s College London, UK

MnM CONFERENCES
10:30-11:40 Morning Refreshments and Poster Presentation Sessions One to one Meetings X3
11:40-12:05
12:05-12:30
Precision Medicine for Cancer CAR-T cell technology Immuno Editing
CONFIRMED:
Prof. Karim Nayernia
Co-Director Head, Institute of Molecular Medicine
Cell Therapy, Düsseldorf, Germany, Heali Institute for
Personalized Medicine, Cambridge, UK
Case study 1: Personalized Therapy of Breast
Cancer
• Personalized medicine has a vision to avoid a costly and
prolonged trial and error approach that can leave the
patient anguishing unnecessarily from side effects, while
simultaneously losing precious time in the fight against the
disease.
• We developed new test, termed as oncoassay, which is a
hybrid assay which combines
• Immunohistochemical analysis, gene expression profiling and
tumor characteristics. This test can help differentiate women who
might benefit from chemotherapy versus those that might not.
• The test analyzes the patterns of several genes within the
cancer cells to help predict how likely it is that a women’s
cancer will recur within 10 years after initial treatment and
how beneficial chemotherapy will be to her. In addition,
oncoassay support physicians to plan a personalized therapy
for cancer patients.
Developing Adoptive Cell Therapy for Cancer:
Progress and Challenges
• Background to Cancer Immunotherapy
• Adoptive Cell Therapy with Natural T-cells
• Engineering T-cells with CAR and TCR
• Manufacturing individualized cell therapy products
• Clinical Trial Design
• Clinical Outcomes – Benefits and Toxicity
CONFIRMED:
Prof. Robert Hawkins
Director of Medical Oncology, University of Manchester,
Christie Hospital Cancer Research UK, UK
Case study 2: Precision Medicine in B Cell
Lymphoma
• Germinal centre lymphomas are addicted to mutations in
their epigenome
• Sequential profiling reveals rich and sparse semblance
between biopsies
• Stability of actionable mutations and precision medicine
CONFIRMED:
Prof. Jude Fitzgibbon
Professor of Personalised Cancer Medicine, Barts Cancer
Institute, Queen Mary University of London, UK
Cancer Immunoediting and Low-level Ionizing
Radiation Therapy
• Concepts of cancer immunosurveillance immunoedition
• Immune reactions in various phases of the cancer immunoediting
process
• Anti-tumour effects of exposures to low-level ionizing
radiation
• Stimulation of anti-cancer immunity by exposures to low-
level ionizing radiation
• Exposures to low-level ionizing radiation in cancer therapy
• Advances in radiotherapy of cancer
CONFIRMED:
Prof. Marek K. Janiak
Head, Dept. of Radiobiology Radiation Protection,
Military Inst. of Hygiene and Epidemiology, Poland

MnM CONFERENCES
12:30-12:55
14:25-14:50
CONFIRMED:
Prof. Stefan Gluck
Vice President, Global Medical Affairs; Breast, Ovarian
Cancer, Immunotherapy, Celgene, USA
Immuno-Oncology: New Developments in Solid
Tumor therapy
• Immunotherapy in solid tumors has been disappointing over
the last several decades
• New molecular approach led to a better understanding of
the immune system
• Check point regulation, understanding roles of Tregs, Th1
and Th2 as well as regulation of DC and Macrophages, led
to discovery of inhibitors and modulators that are currently
used in several solid tumors
• Efficacy in melanoma (led to the FDA approval of one
of the compounds), lung cancer, ovarian cancer and
breast cancer (that were previously thought to be less
immunogenic) was demonstrated and a number of large
clinical trials in all phases are underway
• We will discuss the MoA, its impact on solid tumors, and
some of the early results.
12:55-13:25
For sponsorship opportunities please contact
Steve Hambrook at steve.h@mnmconferences.com
Lunch, One to One Meetings X213:25-14:25
ADC Development Observations and Considerations
to advanced Solid Tumors: Implications to Trial
Design and selection of next generation technologies.
• The number of ADC’s successfully completing phase III
testing and commercialization is limited, especially in solid
tumors.
• That said, most ADCs in development have measurable
anti-tumor effects as early as Phase I testing.
• Agensys (an affiliate of Astellas Pharma Inc.) has tested 4
ADCs to proprietary targets in advanced solid tumors.
• A case study of 2 ADCs against ENPP3 in advanced
refractory renal cell carcinoma will be reviewed including
preclinical, manufacturing , clinical data and phase II plans.
• Implications of the data to manufacturing, clinical
development and selection of next generation
technologies will be discussed.
CONFIRMED
Dr. Leonard M. Reyno
Senior Vice Presidient And Chief Medical Officer
Agensys Inc- Astellas Pharma, USA
Cytology Genetic Detection of Cancer:
Assay development for HTS
Immunotherapy in Solid Tumor
The peritoneal Spreading of Gastric Cancer:
Genetic and Physio-pathological Features,
Multi-modal Treatments
• Natural history of the peritoneal carcinomatosis from
gastric cancer: genetic features, the molecular mechanism
of tumoral spreading and loco-regional implantation.
• Peritoneal cytology and genetic detection of free peritoneal
cancer cells
• Multi-modal treatments: systemic chemotherapy ;cyto-
reductive surgery plus intra-peritoneal chemotherapy; the
role of hyperthermia.
• Therapeutic perspectives: prophylaxis of peritoneal
carcinomatosis; new intra peritoneal agents; target therapy
• A new assay for high-throughput drug screening
CONFIRMED:
Dr. Gianni Mura
Surgical Oncologist and General Surgeon
Valdarno Hospital, Arezzo, Italy
Repurposing FDA-approved Drugs to Eradicate
Cancer Stem Cells, across Multiple Tumour types
• Cancer stem cells need to be targeted to prevent tumor
recurrence, metastasis and drug resistance
• The repurposing of FDA-approved drugs to eradicate
cancer stem cells
• Application to multiple tumor types: breast, DCIS, ovarian,
lung, pancreatic, prostate, melanoma and glioblastoma
• A new assay for high-throughput drug screening
CONFIRMED:
Prof. Michael Lisanti
Director of the Breakthrough Breast Cancer Research Unit,
University of Manchester, UK

MnM CONFERENCES
14:50-15:15
15:40-16:10
Biomarker in Cancer Diagnosis Combinational Therapy for Cancer
Circulating Tumour DNA for Detection and
Monitoring of Cancer
• Why ctDNA as a biomarker for cancer?
• Role in detection and follow up of patients with primary
breast cancer.
• Role in monitoring tumour progression and response to
treatment.
• Can we replace tumour biopsy with liquid biopsy?
CONFIRMED:
Prof. Jacqui Shaw
Department of Cancer Studies
University of Leicester, UK
Case study: Integration of Irreversible
Electroporation with Chemotherapy in the
Treatment of Locally Advanced Pancreatic
Carcinoma
• Natural history of pancreatic cancer
• Current treatment and outcome
• Local regional therapies including Irreversible
Electroporation (IRE) therapy
• Clinical value of IRE in the treatment of locally advanced
pancreatic carcinoma
CONFIRMED:
Prof. Edward Leen
Chair of Radiology, Imperial College London
Imperial College NHS Trust Hammersmith Hospital Campus, UK
15:15-15:40 Mass Spectrometry Proteomics Analysis in
Cancer Detection
Reciprocal Tumour- Stroma Signaling
Tumour Stroma, Mass Spectrometry, Cancer
Progression and Cell Signalling
• Tumour stroma
• Mass spectrometry
• Cancer progression
• Cell signalling
CONFIRMED:
Dr. Claus Jorgensen
Group Leader, Systems Oncology
Cancer Research UK Manchester Institute, UK
Case study 2: The surgical management of
elderly women with breast cancer
• Breast cancer facts figures in older women, Surgery,
Chemotherapy, Radiotherapy, Hormonal therapy,
Reconstruction, Survival, Awareness, Patient’s preference,
Compliance, Frailty assessment.
CONFIRMED:
Prof. Riccardo A. Audisio
University of Liverpool
President, European Society of Surgical Oncologists,
President BASO, UK
Combinational Therapy in Breast Cancer
Afternoon Refreshments atnd Poster Presentation Session
One to One Meetings X2
16:10-17:00

MnM CONFERENCES
17:25-17:50
Nanotechnology in Cancer TherapyGenomics Cellular Characterization
Epigenetics towards Cancer Diagnosis
17:00-17:25
Receptor Signaling approach of Diagnosis
Combinational Therapy: RFA
Immuno stimulation
Evaluating the IFITM1 Receptor Signalling
Pathway as a Therapeutic Target in Human Cancer
• Immunotherapeutics are emerging as compelling
approaches to treat human disease
• A proteogenomics platform was used to facilitate novel
target discovery in cancer
• Pro-metastatic receptors upregulated/mutated in cancer
biopsies were stratified
• IFITM1 is an interferon-inducible membrane receptor
chosen as the priority target
• IFITM1 is implicated in RNA virus restriction and cancer growth/
resistance.
• The IFITM1 signalling pathway is being defined within the
interferon system
• Monoclonal antibodies are being generated to define IFITM1
drugability
CONFIRMED:
Prof. Kathryn Ball
Chair in Biochemistry and Cell Signalling,
Edinburgh Cancer Research Centre, UK
New Methods in Cancer Reversals
• New methods in radiofrequency ablation, combined with
Immune stimulants has shown excellent promise in activation
of the immune system against metastases in the body of
patients
• The results indicate the activation of an endogenous vaccine
against new or preexisting tumors.
CONFIRMED:
Dr. Dana Flavin-König
Executive Director
Foundation for Collaborative medicine and Research, USA
Understanding Prostate Cancer Biology as a
Route to Novel Therapeutics
• Prostate cancer heterogeneity relies on genetic and cellular
diversity.
• Genetic alterations such as ETS fusions regulate AR
signalling and cancer metabolism.
• Prostate luminal lineage is remarkable heterogeneous and
contributes differently to higher grade PCa.
• Knowledge gained by coupling genomics and cellular
characterization will facilitate the development of patient-
specific therapies.
CONFIRMED:
Dr. Esther Baena
Group Leader, Prostate Oncobiology Laboratory
CONFIRMED:
William P. Chastain
Director Founder
APeX Disease Reserch Institute, USA
Hypoxic Micro-Environments may be the
Primary Driver of Uncontrollable Tumor Growth
• Hypoxia induced changes in cancer cells can increase
resistance to coventional therapies
• With hypoxia identified as a key driver of the growth and
spread of cancer, direct oxygen infusion appears to be an
effective therapy
• Artificially Intelligent Hunter-Killer Oxygen Delivery Nano-
Bots deliver active oxygen molecules directly into hypoxic
cancer cells, destroying them instantly
17:50-18:15 Biomarker evaluation of Cancer Therapeutics
Epigenetic Mechanisms for Cancer Risk
• Epigenetic variation may be a driver of cancer risk
whether by inherent constitutional variation or as a
mediator of other cancer risk factors.
• Candidate gene and genome-wide signatures of cancer
risk have been identified.
• Numerous cancer risk exposures also influence the
epigenome.
CONFIRMED:
Dr. James M Flanagan
Non-Clinical Senior Lecturer, Department of Surgery
Cancer, Imperial College London, UK
EAD-box RNA Helicase DP103 as a Biomarker
for Therapeutic Response to Docetaxel
• Interest is increasing rapidly in the use of surrogate
markers as primary measures of the effectiveness of
investigational drugs in definitive drug trials.
• Novel role of DP103 in acquired drug resistance;
presenting a potential surrogate biomarker for predicting
drug response in breast cancer.
• DP103 as the “Gatekeeper” to the “Guardian of the Genome”.
CONFIRMED:
Dr. Alan Prem Kumar
National University of Singapore,
School of Biomedical Sciences, Curtin University, Australia
Chair’s Closing Remarks End of Day118:15-18:20
Drinks Reception18:20-19:00

MnM CONFERENCES
09:40-09:45 Stream Chair: TBC Stream Chair: TBC
Day 2, Friday, September 4th
, London, UK
08.00-08.40 Refreshments One to One MeetingsX2
08.40-08.45 Stream Chair Welcome Address
08:45-09:10 Keynote Address
A Golden Age of Immuno-Oncology: How Did We Get Here Where Are We Going?
• Observations Practice of Visionary Pioneers
• Recent Clinical Success with T Cell Checkpoint Inhibitors
• Pre-Clinical Validation of Emerging Opportunities
• Next Generation Platforms Combinations
CONFIRMED: Dr. James F. Smothers
Sr. Director Head of Discovery Research
Immuno-Oncology Combinations DPU
Oncology RD, GlaxoSmithKline, USA
09:45-10:10
Radiology Imaging in cancer
Interventional Oncological Therapies in the
Treatment of Liver Metastases: Techniques,
Diagnostic and Therapeutic Strategies.
• Use of transarterial chemoperfusion (TACP),
chemoembolization (TACE) and thermal ablation like laser-
induced thermotherapy (LITT), radiofrequency ablation
(RFA), microwave ablation (MWA) and SIRT
CONFIRMED:
Prof. Thomas J. Vogl
Director, Department of Diagnostic Interventional
Radiology, Wolfgang Goethe-University, Germany
Molecular Targeted Therapy in Cancer
Molecular Targeted Therapeutics: Focus on Drug
Resistance
• Drug resistance is multifactorial, but several mechanisms
operate clinically
• Targeting the mechanisms of drug resistance in vitro can
predict response to resistance reversing drugs in vivo
• Biomarkers for resistance and its reversal can be
developed directly from bench to bedside analysis
• A novel pathway mediated through the nuclear
phosphorylation of AKT by DNA-PK in response to
platinum mediated DNA damage operates clinically
• Targeting AKT in the clinic efficiently reverses platinum
resistance in clinical trials suggesting novel strategies for
dealing with the clinical problem of resistance
CONFIRMED:
Prof. Hani Gabra
Professor of Medical Oncology
Director, Ovarian Cancer Action Research Centre,
09:10-09:40
For sponsorship opportunities please contact Steve Hambrook
at steve.h@mnmconferences.com
Diagnosis: Methods, Technology
Applications
Therapy: Methods, Technology
Applications

MnM CONFERENCES
11:35-12:00
11:05-11:35
Morning Refreshments and Poster Presentation Session
One to One MeetingsX3
10:35-11:05
10:10-10:35 Accelerated Partial Breast Irradiation (APBI).
Where are We Today?
• Techniques of APBI, by shortening treatment time, may
increase access to breast-conserving therapy for more
women world-wide.
• Due to decreased irradiated volume, APBI techniques offer
reduced treatment-related toxicity.
• In those cases where chemotherapy is recommended, using
APBI does not delay the start of the treatment.
• Numerous trials (ongoing and recently completed) in US
and Europe.
• Consensus guidelines do exist to help appropriate patient
selection, while trial data mature.
CONFIRMED:
Dr. Christos Christopoulos
Consultant, Radiation Oncologist
Metropolitan Hospital, Greece
CONFIRMED:
Prof. Peter Parker
London Research Institute CRUK, Lincoln’s Inn Fields,
King’s College London, UK
Targeting Kinases in Cancer
• Protein and lipid kinases are characteristically engaged
in the regulatory hierarchies that govern cell behaviour.
These proteins are disproportionately represented in
the mutational cancer genome, indicative of selection for
altered functions driving the cancer phenotype. Kinases are
druggable, with over 20 drugs now approved for use and
a large number in the development pipeline.
• The delivery of a kinase target clinically, involves
many facets typical of small molecule discovery and
development programmes. Co-development of biomarkers
as pharmacodynamic markers and stratification markers is
increasingly seen as an important dimension for these targeted
therapeutics. Approaches to these objectives and some of the
technologies for delivering them will be addressed in the
context of the protein kinase development pipeline.
Molecular Targeted Drug Discovery: From
Concept to Clinic
• Kinase inhibitor drug discovery (2 kinase inhibitors in the
clinic-AZD5363 and AT13148)
• This will cover aspects from target validation, drug discovery
and phase I clinical trial
• Will emphasise the role of Pharmacodynamic biomarkers in
Phase I clinical trials
• Will end with the topic of drug resistance
CONFIRMED:
Prof. Michelle Garrett
University of Kent, General Secretary
The British Association for Cancer Research, UK
Imaging technology for Cancer Diagnosis
• Technological advancements
• Case studies
• Vascular/Interventional technologies
• Image analysis Tumor response measurement
SPEAKER: TBC
Radiology Imaging in cancer Molecular Targeted Therapy in Cancer

MnM CONFERENCES
11:35-12:00
12:25-12:50
RT-PCR/ qPCR in Cancer Diagnosis
• Technology prospective
• Gene quantification using immune-histochemically identified
biopsies
• Organ specific cancer case study
New Approaches to Inhibiting Androgen
Receptor Signalling in Advanced Prostate
Cancer
• Prostate cancer growth is dependent upon the Androgen
Receptor (AR) pathway. However,hormonal therapies
eventually fail and tumours progress to castrate resistant
disease (CRPC).
• The AR remains key to CRPC growth so new methods to
inhibit androgen signalling in CRPC are urgently needed.
AR activity is modulated by coactivators that increase and
corepressors that decrease its activity. We are exploiting
these, and the interplay of androgen and microRNA
signalling, to develop new approaches to inhibition of the
androgen response.
• Therapeutic inhibition of androgen signalling has significant
side effects in other tissues. We have developed an in
vivo model for physiological/developmental analysis
of androgen signalling and evaluation of SARMs and
other novel androgen signalling inhibitors, with the aim
of producing potent, tissue-selective future therapies for
prostate cancer.
CONFIRMED:
Prof. Charlotte Bevan
Imperial Centre for Translational Experimental Medicine,
The Social Nature of Cancer Cells, Call to Target
the Microenvironment
• Cancer cells in vivo are not self-sufficient, they require
building new interactions with the host cells of the tissue
influencing their behaviour.
• Metastatic cancer cells require the generation a favourable
microenvironment (or niche) supporting their growth at a
secondary site.
• Identifying and targeting the crucial mediators of cancer-
niche cells cross talk can represent an important approach
to develop more effective anti-cancer strategies.
CONFIRMED:
Dr. Ilaria Malanchi
Group Leader, Tumour Host Interaction Lab, Cancer
Research UK, London Research Institute, UK
SPEAKER: TBC
Next-Generation Sequencing (NGS)
application in Cancer Diagnostics
• Applications of Sequencing technology
• Identification of mutated genes
• Data analysis interpretation
SPEAKER: TBC
PCR in Cancer Diagnosis Molecular Targeted Therapy in Cancer

MnM CONFERENCES
14:00-14:30
15 minutes small company showcase presentation X2
(To Be Confirmed)
15 minutes small company showcase presentation X2
(To Be Confirmed)
Lunch and Poster Presentation Session13:15-14:00
12:50-13:15
14:30-14:55
Modulating Cancer-associated Fibroblasts to
Deter Tumour Progression
• Cancer-associated fibroblasts (CAFs) are prevalent non-
malignant stromal cells that critically regulate tumorigenesis
• Targeting CAFs represents a new therapeutic modality to
deter malignant progression
• Understanding the pathologically activated status of CAFs
is crucial to design strategies to reprogram them towards
normal anti-tumorigenic phenotypest.
CONFIRMED:
Dr. Fernando Calvo
Team Leader, Tumour Microenvironment Team
The Institute of Cancer Research, UK
Regulatory updates in Cancer Research
Genetics Epigenetics Approach
towards Cancer Therapy
Biobanking International Harmonization
Globalization
• Goals objectives
• Prospects for harmonisation networking
• IPAC: Sharing global data
CONFIRMED:
Prof. Pedro Rondot Radíot
University of Buenos Aires, Army Social Security
Argentina
Identifying Novel Epigenetically Induced
Synthetic Lethality Therapeutic Combinations for
High Risk MDS/AML
• Several types of myeloid leukaemia have an epigenetic
signature
• Epigenetic therapies have been used with some effect for
these diseases
• Rational novel combination therapies can be identified
by studying the molecular consequences of the epigenetic
modifiers
CONFIRMED:
Prof. Ken Mills
Chair of Experimental Hematology, CCRCB
Queen’s University Belfast, UK
Mass Spectrometry in Cancer Diagnosis
• Technological aspect
• Data analysis
• Proteomics profiling assay development
SPEAKER: TBC
Spectroscopy in Cancer Diagnosis Molecular Targeted Therapy in Cancer

MnM CONFERENCES
14:55-15:20
15:20-15:45
Real World Evidence in Oncology
• Oncology Research Waste or Real World Gaps
• Real World Evidence Methodology
• RWE best practices in Oncology
CONFIRMED:
Dr. Francisco Gonzalez
Hemato - Oncology Medical Manager
The Janssen Pharmaceutical Companies of Johnson Johnson,
Panama
The Role Of Protein Homeostasis In The Genesis Of
Cancer
• Protein homeostasis and diseases
• Protein homeostasis in the nucleus its influence on the genome
stability and protection from cancer
• How the lost of protein homeostasis leads to genome instability
and consequently cancer
•Identification of the first gene essential for nuclear protein
homeostasis which mutations lead to cancer
• How the nuclear protein homeostasis could be used as a
therapeutic window for cancer therapy
CONFIRMED:
Prof. Kristijan Ramadan
CRUK/MRC Oxford Institute for Radiation Oncology
Department of Oncology, University of Oxford, UK
What Value do Patients Place on Drugs
Offering PFS Benefits
• There are many novel drugs available approved on the
basis of a PFS benefit
•Drugs that excite the clinical scientist may not be of great
benefit to patients suffering the side effects of treatment
unless disease symptoms improve
• Assessing the Value to Patients OF Progression Free
Survival (AVALPROFS) is a longitudinal study probing
the value pts themselves place on treatments they are
currently receiving that offer only PFS benefits
• We also examine the proportion of pts in general whom
oncologists estimated would derive medical benefit
from the drug on offer (ORR) and their predicted likely
benefits for individual pts such life expectancy with or
without further tmt
• Progression Free Survival is an ambiguous, misleading
term and should be replaced by Progression Free Interval
to assist understanding of true therapeutic aims
CONFIRMED:
Prof. Lesley Fallowfield
Director: SHORE-C, Brighton Sussex Medical School,
University of Sussex, UK
MicroRNAs in Lung Tumorigenesis and Response
to Chemotherapy
• MicroRNAs are differentially expressed in normal and tumor
tissues.
• MicroRNAs are key players in cancer onset and progression.
• Modulation of microRNAs blocks tumorigenesis and improves
response to chemotherapy.
CONFIRMED:
Dr. Michela Garofalo
Group Leader, Transcriptional Networks in Lung Cancer,

MnM CONFERENCES
14:55-15:20
Chairperson’s closing Remarks Conference Close16:10-16:15
Afternoon Refreshments16:15
NCRN Hepatobiliary Trials Portfolio
• Overview of the NCRN
• Focus on the Hepatobiliary trials portfolio
• surgical trails in Colorectal liver metastases
• HCC Cholangiocarcinoma
CONFIRMED:
Hassan Z Malik
University Hospital Aintree, Honorary Secretary
British Association of Surgical Oncology UK
Epigenetic Drivers of Drug Resistance
• Drug resistance is a major obstacle in the successful
treatment of cancer
• Epigenetic mechanisms of gene silencing can be an
important driver of drug resistance
• Changes in DNA methylation can be observed in drug
resistant ovarian tumours
• Epigenetic therapies have potential to overcome drug
resistance
CONFIRMED:
Prof. Robert Brown
Head of Division of Cancer / Chair in Translational Oncology,

MnM CONFERENCES
Media Partners
Sponsors

Cancer-Diagnosis-and-Therapy-Congress-17June

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (20)

Ähnlich wie Cancer-Diagnosis-and-Therapy-Congress-17June

Ähnlich wie Cancer-Diagnosis-and-Therapy-Congress-17June (20)

Cancer-Diagnosis-and-Therapy-Congress-17June